Deep Functional and Molecular Characterization of a High-Risk Undifferentiated Pleomorphic Sarcoma. by Berlow, Noah E et al.
The Jackson Laboratory 
The Mouseion at the JAXlibrary 
Faculty Research 2020 Faculty Research 
1-1-2020 
Deep Functional and Molecular Characterization of a High-Risk 
Undifferentiated Pleomorphic Sarcoma. 
Noah E Berlow 
Catherine S Grasso 
Michael J Quist 
Mingshan Cheng 
Regina Gandour-Edwards 
See next page for additional authors 
Follow this and additional works at: https://mouseion.jax.org/stfb2020 
 Part of the Life Sciences Commons, and the Medicine and Health Sciences Commons 
Authors 
Noah E Berlow, Catherine S Grasso, Michael J Quist, Mingshan Cheng, Regina Gandour-Edwards, Brian S 
Hernandez, Joel E Michalek, Christopher Ryan, Paul Spellman, Ranadip Pal, Lynn S Million, Mark Renneker, 
and Charles Keller 
Research Article
Deep Functional and Molecular Characterization of a High-Risk
Undifferentiated Pleomorphic Sarcoma
Noah E. Berlow ,1,2,3 Catherine S. Grasso,3 Michael J. Quist,3 Mingshan Cheng,4
Regina Gandour-Edwards,5 Brian S. Hernandez,6 Joel E. Michalek,6 Christopher Ryan,7
Paul Spellman,7 Ranadip Pal ,2 Lynn S. Million ,8 Mark Renneker ,9,10
and Charles Keller 1,2
1Children’s Cancer erapy Development Institute, Beaverton, OR 97005, USA
2Electrical and Computer Engineering, Texas Tech University, Lubbock, TX 79409, USA
3Division of Hematology-Oncology, University of California, Los Angeles, CA 90095, USA
4e Jackson Laboratory, Bar Harbor, ME 04609, USA
5Department of Pathology & Laboratory Medicine, UC Davis Health System, Sacramento, CA 95817, USA
6Department of Epidemiology and Biostatistics, University of Texas Health Science Center San Antonio, San Antonio,
TX 78229, USA
7School of Medicine, Oregon Health and Science University, Portland, OR 97239, USA
8Department of Radiation Oncology, Stanford University, Stanford, CA 94305, USA
9Patient-Directed Consultations, San Francisco, CA 94116, USA
10Department of Family Medicine, University of California San Francisco, San Francisco, CA 94143, USA
Correspondence should be addressed to Noah E. Berlow; noah@cc-tdi.org, Lynn S. Million; lmillion@stanford.edu,
Mark Renneker; mark.renneker@ucsf.edu, and Charles Keller; charles@cc-tdi.org
Received 9 December 2019; Revised 7 February 2020; Accepted 10 February 2020; Published 1 June 2020
Academic Editor: Cornelis Verhoef
Copyright © 2020 Noah E. Berlow et al. 0is is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Nonrhabdomyosarcoma soft-tissue sarcomas (STSs) are a class of 50+ cancers arising in muscle and soft tissues of children, adolescents,
and adults. Rarity of each subtype often precludes subtype-specific preclinical research, leavingmany STS patients with limited treatment
options should frontline therapy be insufficient. When clinical options are exhausted, personalized therapy assignment approaches may
help direct patient care. Here, we report the results of an adult female STS patient with relapsed undifferentiated pleomorphic sarcoma
(UPS) who self-drove exploration of a wide array of personalized Clinical Laboratory Improvement Amendments (CLIAs) level and
research-level diagnostics, including state of the art genomic, proteomic, ex vivo live cell chemosensitivity testing, a patient-derived
xenograft model, and immunoscoring. Her therapeutic choices were also diverse, including neoadjuvant chemotherapy, radiation
therapy, and surgeries. Adjuvant and recurrence strategies included off-label and naturalmedicines, several immunotherapies, andN-of-
1 approaches. Identified treatment options, especially those validated during the in vivo study, were not introduced into the course of
clinical treatment but did provide plausible treatment regimens based on FDA-approved clinical agents.
1. Introduction
Nonrhabdomyosarcoma soft-tissue sarcomas (NRSTSs)
are a collection of 50+ soft-tissue tumors occurring from
infancy to geriatric ages. Due to rarity of each subtype and
limited preclinical research models, individual NRSTS
subtypes remain underserved from the basic science and
preclinical investigation perspective. 0e few established
clinical trials often treat NRSTS as a group rather than a
spectrum of individual diseases (e.g., NCT02180867 and
NCT02267083). Distant metastasis is the major cause of
death in NRSTS [1]. Inconsistent response to chemo-
therapy makes complete surgical resection an essential
aspect of NRSTS therapy.
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A retrospective study of adult soft-tissue sarcoma pa-
tients analyzed survival following surgical resection based on
a modified Union for International Cancer Control (UICC)
tumor-node-metastasis (TNM) criterion. 0e two criterion
are R0M (resection with clear margins including satellite
nodules and proliferation contours) and R1M (resection
with infiltrated margins including satellite nodules and
proliferation contours). 0irty-eight percent of NRSTS
patient surgeries were classified as R1M (incomplete re-
section). When segmented by R0M/R1M status, the 5-year
local recurrence-free survival (LRFS) following R0M/R1M
surgery was 92%/63% (p � 0.001) [1], the 5-year disease-free
survival (DFS) was 69%/32% (p< 0.001) [1], and the 5-year
metastasis-free survival (MFS) was 75%/43% (p � 0.007) [1].
Among patients with initially unresectable tumors who
received chemotherapy or local radiotherapy, the 5-year
survival rate following local recurrence/progression is 9%
[2, 3]. Statistics for UPS show the limitations of current
clinical standard of care, where 38% of NRSTS patients
expect ∼30% difference in 5-year survival based on surgical
outcomes alone. New therapies are critically needed to
address unresectable tumors, residual local disease, and
distant metastasis of tumors to improve outcomes for
NRSTS patients.
0eNRSTS undifferentiated pleomorphic sarcoma (UPS),
formerly known as malignant fibrous histiocytoma (MFH),
is an aggressive malignant soft-tissue or bone sarcoma
arising both distally and proximally [4, 5]. UPS is the 4th
most common soft-tissue sarcoma with approximately 3
cases per 100,000 persons/year [6] and occurs across the age
spectrum, afflicting pediatric, young adult, and adult pa-
tients, although UPS occurs most commonly in 60–80-year-
old patients. UPS is often characterized by presence of a
tumor mass resulting in swelling, pain, cancer-induced
pathological bone fracture, and additional systemic features
[4, 5]. UPS has both a high rate of recurrence and significant
metastatic burden (distant metastases more likely than re-
gional, with lungs as the most frequent metastatic site) [4, 5].
Overall 5-year survival for head and neck UPS tumors is 48%
versus 77% for trunk and extremity UPS cases [4, 5]. Here,
we present the case of an adult female patient with UPS, with
a focus on multiple approaches explored for personalization
of therapy. A timeline of treatments and events is provided
in Supplemental Figure 1.
2. Results
2.1. Clinical Presentation. Our index case is a 61-year-old
female with a history of bilateral breast cancers, basal cell
carcinoma, and multiple lipomas. She presented with a
swollen, painful right posterior thigh found on imaging to
contain a 14 cmmass. Tru-cut® biopsy revealed a high-grade(FNLCC grade 3) undifferentiated sarcoma. No evidence of
metastases was found on additional imaging, and she was
assessed as stage III, T2bN0M0.
2.2. Initial Treatment. 0e patient began with neoadjuvant
therapy at her local cancer center, consisting of one cycle of
doxorubicin and ifosfamide, followed by 2 cycles of ifos-
famide with concurrent radiation therapy which elicited
approximately 30% tumor reduction. A wide excision sur-
gical plan that would include part of her femur was pro-
posed. To avoid sacrifice of bone and the sciatic nerve, she
opted for six additional rounds of higher dose chemotherapy
consisting of 4 cycles of doxorubicin and ifosfamide fol-
lowed by two cycles of gemcitabine and docetaxel which
resulted in approximately 67% tumor size reduction but with
increasing toxicities. After 9 months of neoadjuvant che-
motherapy, the patient underwent bone and sciatic nerve-
sparing surgery at a specialized cancer center. Clear margins
were achieved. Pathology revealed a 5 cm pleomorphic
spindle cell sarcoma, the majority of which had a lowmitotic
rate, except for an embedded 2 cm area of higher grade
disease which showed up to 58 mitoses/hpf. Treatment effect
was evident from histopathology. 0ree additional cycles of
adjuvant chemotherapy with doxorubicin and ifosfamide
were recommended, but the patient only tolerated one cycle.
2.3. Exploration of erapeutic Options. During the second
round of neoadjuvant therapy, the patient came to realize
her risk of recurrence was considerable and decided to
expand her knowledge of soft-tissue sarcomas and explore
the state of sarcoma research, trials, and expertise at insti-
tutions outside her treating institution. Adjuvant therapy
clinical trials that might apply to her case were sought, but
none were available. As such, she decided to use her re-
sources and professional management experience to in-
vestigate her own therapeutic regimens and research
resources.
0e patient enlisted the ongoing help of an experienced
medical advocate physician (coauthor M. R.) to provide her
with information relevant to her disease type and help her
explore potential strategies to overcome limited information
and research available for her comparatively rare cancer.0e
patient subsequently pursued numerous nonstandard
therapeutic options in the pursuit of effective and durable
treatment response. To explore nonstandard therapy op-
tions, tumor tissue from surgical resection was sent to
multiple laboratories for analysis, hoping that more precise
and less toxic adjuvant therapy recommendations would
emerge.
2.4. Commercial Ex Vivo Chemosensitivity Assays. Live
surgically excised tumor tissue was processed to create a
primary cell culture which was then exposed to various
single agent and combination chemotherapy and/or targeted
therapy drugs associated with sarcoma. Two independent
commercial laboratories (Rational 0erapeutics and Wei-
senthal Lab) tested drug efficacy on the basis of programmed
cell death chemosensitivity using similar laboratory
methods. Commercial chemosensitivity testing identified,
with interlaboratory concordance (4 of 8 tested agents with
identical interpretation, Supplemental Table 1), several
drugs to which the tumor might be sensitive, including
vorinostat, interferon-alfa, dacarbazine, oxaliplatin, Serratia
marcescens (Coley’s toxin), artemisinin, phenylbutyrate, the
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combination of cisplatin and gemcitabine, and the combi-
nation of vinorelbine and lapatinib (Supplemental Table 1).
Resistance or low sensitivity was predicted for drugs the
patient had previously been treated with including doxo-
rubicin, ifosfamide, gemcitabine, and taxotere (Supple-
mental Table 1). Based on the ex vivo chemosensitivity
results and quality-of-life challenges from previous rounds
of high-dose chemotherapy, the patient elected to not pursue
further use of the chemotherapy agents predicted to be
resistant by the chemosensitivity assays. A separate research-
level sensitivity assay performed at Oregon Health and
Science University (OHSU) is presented in a later section.
Concordance between the commercial ex vivo assays and the
research-level sensitivity assay is provided in Supplemental
Table 2.
2.5. Immunotherapy. 0e patient also pursued cancer im-
munotherapy, focusing on maintenance immunotherapy
protocols presented at the Annual Meetings of the American
Association of Cancer Research [7]. Subsequently, a local
integrative physician prescribed the patient a modified
Recchia protocol using low-dose subcutaneous interleukin 2
(1–1.2 million units) and oral cis-retinoic acid (0.5mg/kg)
three times weekly, every other week.0e patient was able to
obtain and use maintenance immunotherapy based on a
subcutaneous thymic stimulator called thymosin-alpha
(1.6mg twice weekly) [8] which has been approved outside
the US. She also arranged to have leukapheresis and to
receive a personalized dendritic cell vaccine [9].
2.6. Additional Wellness Approaches. Terrain testing was
performed to identify potentially actionable blood levels of
various vitamins, minerals, inflammatory markers, coagu-
lation markers, and immune markers, which lead to sup-
plementation with specific vitamins (particularly vitamin
D), curcumin, green tea extract, omega-3 fatty acids, and
mushroom extracts. 0e patient also optimized her sleep
schedule and engaged in various Mind-Body approaches,
including an aggressive physical therapy and training pro-
gram to recover from the surgery and to improve her
physical health.
2.7. Xenograft Model Development. Tissue samples from the
patient’s tumor (denoted PCB-209) were sent to our labo-
ratory following surgical resection of tumor tissue. From the
live tissue sample, a primary cell culture was created, a
research-level targeted agent sensitivity panel was per-
formed, and whole genome and transcriptome sequencing
was performed through sequencing partners. Tumor tissue
was shared with the Jackson Laboratory (JAX), where a
patient-derived xenograft (PDX) was established in a mouse
(PDXmodel TM00381) to enable downstream assessment of
potential chemotherapeutic and targeted therapy drugs.
Log-scaled expression data showed high correlation
(ρ� 0.9432) between PCB-209 primary tumor and PCB-209
PDX tumor (Figure 1(a)), and hematoxylin and eosin stain
analysis of primary tumor tissue versus PDX tumor tissue
(Figures 1(b) and 1(c)) showed consistent histology before
and after engraftment. Representative IHC images for PCB-
209 show presence of proteins of interest from morpho-
proteomic analysis or published UPS biology [10, 11]
(Figures 1(d)–1(h)).
2.8. Research-Level Chemosensitivity Assay. Primary PCB-
209 tissue was cultured and subsequently screened with the
PPTI Version 2.1 single agent chemical screen. Due to slow
primary culture cell growth, PCB-209 primary culture was
screened on only 19 of 60 agents (Supplemental Table 3).
Tumor tissue explanted from the established PCB-209 PDX
mouse model was cultured and also screened with the PPTI
Version 2.1 single agent chemical screen (Supplemental
Table 3). Comparison of primary culture vs. PDX response
data showed sensitivity to CDK9 inhibition (alvocidib) in the
primary culture; sensitivity to Mao/autophagy pathway
inhibition (quinacrine) and GLI1/2 inhibition (GANT 61) in
the PDX culture; and concordance in sensitivity to
proteasome inhibition (carfilzomib) and ALK/MET inhi-
bition (crizotinib). Moderate crizotinib sensitivity was
consistent across the research-level screen and the com-
mercial screen. Chemical screening identified a total of 16
compounds with activity for the PCB-209 PDX cell culture.
2.9. Genomic and Transcriptomic Profiling. DNA and RNA
isolated from PCB-209 primary tumor tissue were sent for
whole genome and whole transcriptome sequencing. Ge-
nomic profiling was largely by Next Generation Sequencing
(NGS), performed by Foundation Medicine, Caris, and the
Genomic Profiling Shared Resource at OHSU.
Ten actionable alterations were noted, including several
FGF genes, CCND1 and EMSY amplified genes, ALK gain,
TP53 and CDKN2A/B losses, and a mutation of ATRX
(F529fs). No FDA-approved drugs or sarcoma-specific
clinical trials matched the identified gene abnormalities.
NGS also identified 12 variants of unknown significance. At
the time, the genomic profiling was performed, and status of
microsatellite genes was not reported. Nonetheless, all three
tested microsatellite-related genes (MSH2, MSH6, and
PMS2) were intact.
Because the genomic profiling results were not clinically
actionable, the patient commissioned a literature review to
examine published research on the identified gene abnor-
malities and abnormalities in the variant genes in general
(i.e., not for the patient’s specific mutation) for all 22 variant
genes to identify possible off-label medications or natural
products with published activity. 0e majority of variant
genes had associated citations from cell line-based experi-
ments, which were used to further personalize her adjuvant
supplement plan.
RNA isolated from PCB-209 primary tumor tissue and
PCB-209 PDX explant tissue was also sent for transcriptome
sequencing to determine overall gene expression and
identify systemic changes in gene expression following PDX
establishment. Genomic and transcriptomic data are sum-
marized in Circos plot format (Figure 2) and in tabular
format (Supplemental Table 4).
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2.10. Morphoproteomic Immunohistochemistry Analysis.
Morphoproteomic analysis (immunohistochemistry panel)
qualifies and quantifies protein expression from formalin
fixed, paraffin embedded (FFPE) tissue slides to identify
patient-specific treatment options. Morphoproteomic
analysis by immunohistochemistry was performed by the
Brown Laboratory at the University of Texas Health Science
Center Houston [12] and focused on the higher-grade
portion of the tumor which showed IGF1R and PRKCA as
the principal upstream signal transducer drivers and mTOR
as a downstream effector. Areas of high protein expression of
COX2, SIRT1, STAT3, HIF1A, PPARG, NES, CD133, GLI2,
and SPARC were also identified. Recommendations in-
cluded albumin-bound paclitaxel and off-label agents or
natural medicines including metformin, COX2 inhibitors,
vorinostat, and melatonin. Morphoproteomic analysis
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Figure 1: RNA-seq and histology of PCB-209. RNA-seq data for PTIM identified targets andmultiple staining images of PCB-209. RNA-seq
and histology data were used to partially guide cohorts of the in vivo PDX trial. (a) RNA-seq expression of PCB-209 vs. PCB-209 PDX. (b)
H&E stain. (c) PDX H&E stain. (d) Staining for COX2. (e) Staining for GLI2. (f ) Staining for ki67. (g) Staining for pERK. (h) Staining for
PRKCA. (i) RNA-seq RPKM reported in log2 format for targets identified by the PTIM analysis informed with RNA-seq data. Red indicates
high expression, and green indicates low expression.0e left column is the expression for the original cell culture, and the right column is the
expression for the culture created from the xenograft mice.
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Figure 2: Circos plot of PCB-209 RNA sequencing and whole genome sequencing data. 0e outermost data circle represents log2-
scaled gene expression (green represents negative, red represents positive) for genes with identified mutations or copy number
variations. 0e middle circle represents genes with identified mutations or indels (black) or lack thereof (white). 0e innermost circle
represents copy number variations (pink is amplification, light blue is deletion, and white is no variation). Genes which carry both
mutations and amplifications (TNS3, BRINP1, RABEP1, and CDH4) are written in blue around the circle, as are genes relevant to in
vivo studies (HDAC1, ALK, GL1, HDAC3, FLT4, PSMB8, HDAC2, JAK2, PSMB5,MAP2K1, PRKCA, BCL2,MAP2K2, AKT2, BCL2L1,
and MAPK1).
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recommendations referenced cell-line and animal studies.
0e patient chose to forego the chemotherapies and HDAC
inhibitor but did begin on metformin (850mg/day), a COX2
inhibitor, and melatonin (20mg/night). Morphoproteomic
analysis results are presented in Supplemental Table 5.
2.11. Probabilistic Target Inhibition Map Modeling.
Probabilistic Target Inhibition Map (PTIM) modeling
[13–18] integrates patient-specific chemical screening data
with matched genomic and transcriptomic sequencing data
to design personalized drug combinations. PTIM modeling
identifies drug combinations where the individual agents
may not slow or stop tumor growth but in combination will
be synergistic and slow tumor growth. PTIM modeling
analysis of PCB-209 PDX chemical screening data
(Figure 3(a)) with integrated PCB-209 genomic and tran-
scriptomic sequencing data (Figure 3(b)) identified multi-
target explanations for in vitro chemical screen sensitivities
and was used to predict an efficacious drug combination,
ABT-737 (BCL2 inhibitor) with midostaurin (multikinase
inhibitor). PTIM modeling is independent of morphopro-
teomic analysis and integrated only the PCB-209 PDX
chemosensitivity assay data and genomic and transcriptomic
profiling data (Supplemental Table 6).
2.12. Patient-Derived Xenograft erapy Selection and
Validation. 0e patient-derived xenograft model estab-
lished from the patient’s tumor was used to perform in vivo
testing of multiple potential treatment options. Results from
in vivo testing are presented as tumor volumes 21 days
following initiation of treatment, selected as the experi-
mental endpoint (Figure 4).
2.12.1. Whole Genome Sequencing. Whole genome se-
quencing identified several nonactionable variants, in-
cluding amplification in the ALK gene. While not
specifically linked to ALK amplification, PCB-209 showed
moderate sensitivity to crizotinib in vitro (Supplemental
Table 3); thus, the ALK-inhibitor crizotinib was selected
for in vivo PDX validation, which showed no statistically
significant slowing of tumor growth versus control
(p � 0.5, Figure 4(a)).
2.12.2. Chemical Screening. Two clinically available com-
pounds with the lowest absolute IC50 values (panobinostat,
pan-HDAC inhibitor, and carfilzomib, proteasome in-
hibitor) were selected from the research-level chemo-
sensitivity assay for in vivo PDX validation. Panobinostat
also showed efficacy on the PCB-209 primary culture
(Supplemental Table 3). Both panobinostat and carfilzo-
mib inhibit targets were found to be expressed in both
primary and PDX tumor tissue (Figure 1(i)). Carfilzomib
showed no statistically significant slowing of tumor growth
(p � 0.2, Figure 4(b)), while panobinostat showed statis-
tically significant slowing of tumor growth (p< 0.05,
Figure 4(c)).
2.12.3. Immunohistochemistry Analysis. Immunohisto-
chemistry-based analysis results and evidence of existing
drug synergy [19] motivated the selection of celecoxib
(COX2 inhibitor) and trametinib (a MEK inhibitor not
identified by morphoproteomic immunohistochemistry
(IHC) profiling) for in vivo validation. 0e celecoxib and
trametinib combination showed a possible in vivo effect but
was not statistically significant (p � 0.5, Figure 4(d)).
2.12.4. Probabilistic Target Inhibitor Map Modeling.
PTIM modeling of PCB-209 data guided selection of the
combination of ABT-737 with midostaurin for in vivo
validation. Individually, both ABT-737 and midostaurin
were predicted to not show efficacy in vivo but in combi-
nation would show synergy and efficacy.
As predicted, PTIM-guided single agents did not show
statistically significant slowing of tumor growth (p � 0.148,
Figure 4(e)). Due to low replicates at conclusion of the in
vivo experiment, the PTIM-guided combination could not
be analyzed for statistical significance. However, the PTIM-
guided combination was tracked at the lowest tumor volume
in vivo (µ� 450mm3, Figure 4(e)).
2.13. Recurrence and Outcome. Fifteen months after her
initial surgery and extending over the next approximately 18
months, imaging by PET/CT (less so physical examination)
showed soft-tissue changes in her thigh strongly suggestive
of local recurrence, leading to several additional surgical
procedures. 0ree times, only benign tissue changes were
found, but twice malignant cells were discovered. Notably,
histochemical assessment in both the benign sites and re-
currence sites showed considerable immune activation (in
the malignant tissue, there were up to 49 CD8+ tumor
infiltrating lymphocytes per high powered field). Finally,
approximately 3.5 years after her initial diagnosis, the dis-
ease became broadly invasive into her upper leg, requiring
right leg amputation. Within weeks, rapidly growing disease
was then found in her pelvis and lower abdomen. A brief
course of off-label ipilimumab and pembrolizumab was
attempted, but the patient soon died.
0e Probabilistic Target Inhibitor Map (PTIM) model
presented in Figure 3 captures 3 cohorts of the trial: the
first PTIM block identifies panobinostat (panel C), a highly
selective HDAC inhibitor, as a viable treatment option.
Block 2 identifies carfilzomib, a proteasome inhibitor, as a
viable option. Block 3 in the RNA-seq-informed model
(Block 4 in the naive model) identifies a combination of
ABT-737 (a BCL2 and BCL2L1 inhibitor) and midostaurin
(an AKT2 inhibitor) as a viable treatment option. Cri-
zotinib was identified due to PCB-209 showing in vitro
response to crizotinib and the presence of an ALK am-
plification. 0e morphoproteomic approach identified
metformin, vorinostat, melatonin, and celecoxib in con-
junction with Abraxane as viable treatments, which in-
spired the combination of celecoxib and trametinib (a
MEK inhibitor not identified by IHC profiling) for vali-
dation due to existing evidence of drug synergy [19]. Of
note, vorinostat is a pan-HDAC inhibitor similar to
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panobinostat, which showed in vivo efficacy, but had IC50
above clinically achievable concentrations. 0e IHC-mo-
tivated regimen was developed independently using
morphoproteomic data provided by Dr. Robert Brown of
the University of Texas Medical School in Houston. Dr.
Brown’s recommendations were not precisely followed;
thus, we term the combination of celecoxib and trametinib
“IHC-motivated”. 0e IHC-motivated combination did
not involve the PTIM modeling approach in any way.
Due to small cohort size resulting from technical con-
siderations at the Jackson Laboratory, the ABT-
737 +midostaurin cohort cannot have a complete statistical
analysis generated. However, the individual drugs identified
by the chemical screen and PTIM model showed in vivo
activity, and ABT-737 +midostaurin trends to a synergistic
effect. Overall, two of three treatment options were po-
tentially relevant, with ABT-737 plus midostaurin and
panobinostat able to slow in vivo tumor growth. Note that,
for the ABT-737 plus midostaurin arm in panel (E), both
drugs independently have mild capacity to slow tumor
growth but in combination appear to provide greater re-
duction of tumor growth.
3. Discussion
While precision/personalized therapy selection ap-
proaches did not result in the addition of targeted ther-
apeutic agents to the patient’s clinical course, the
development of patient-specific preclinical models and
datasets has the potential to enable transformative per-
sonalized cancer care. Additionally, the patient elected to
alter her supplemental health choices and clinical deci-
sions based on the data provided to her through multiple
assays. Median length of survival after diagnosis for high-
grade UPS is 9.6 months (8.2 months to 11.4 months, 95%
CI) [20]. Despite a prior history of multiple cancers, the
patient survived 3.5 years following her UPS diagnosis and
16 months following relapse.
As tools for therapy selection, each model develop-
ment and analysis approach carries inherent strengths and
weaknesses. While a PDX model was established for PCB-
209, roughly 50% of patient tumors will not engraft [21].
Additionally, the timeline for model establishment and
the cost of PDX development and testing can be pro-
hibitive to many patients, despite the high predictive
accuracy (∼87%) of low-passage PDX models [21]. Mo-
lecular sequencing of patient tumors is now a fast, robust
and economical option. However, approximately 60% of
patients bear no actionable sequencing results [22, 23],
and single drug therapy often fails to sustainably control
disease progression [24]. Morphoproteomics and similar
IHC-based approaches interrogate presence of proteins in
tumor cells, which are often the interacting partners with
targeted therapies. Unfortunately, IHC-based approaches
remain lower throughput than sequencing-based ap-
proaches and thus limit the scope of analysis to a small set
of genes. Functional approaches provide evidence of the
intervention effect via targeted therapy agents (as in the
PTIM approach) or single target knockdown of individual
genes (as in high-throughput siRNA screens, not per-
formed for the patient’s tumor), which can be the critical
data needed for clinical decision-making. Functional
approaches rely on availability of fresh and viable tumor
tissue which can result in logistical challenges or may be
inaccessible if insufficient tumor tissue is available. Se-
lection of the proper technologies and approaches for
development of personalized treatment will depend on
availability of time, tissue, and financial resources.
Nonetheless, the need for advancing clinical use of pre-
cision and personalized medicine is overwhelming for the
600,000 patients lost to cancer every year [5].
0e PCB-209 case is representative of the numerous
enigmatic and high-risk UPS cases that occur every year.
However, we uncovered important functional relationships
and actionable targets and compounds that may be of po-
tential value for understanding and treating UPS en masse
for future patients. Additionally, this case report serves as a
stark reminder of the lack of clinical trials or clinically
validated treatment options for UPS once frontline therapy
no longer controls disease. While development of additional
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Figure 3: Probabilistic Target Inhibitor Map (PTIM) model of the PCB209 xenograft-derived chemical screen. Orange text indicate targets
inhibited by ABY-737; blue text indicates targets inhibited by midostaurin. (a) Pediatric preclinical testing initiative (PPTI) 60 chemical
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preclinical resources and sequencing experiments will help
to progress the scientific understanding of UPS, the rarity
and frequency of recurrence necessitate identifying per-
sonalized treatment options for recurrent UPS whenever
feasible, especially when personalization would be the only
path to a viable therapy.
4. Methods
4.1. Cell Model Establishment. 0e human undifferentiated
pleomorphic sarcoma (UPS) sample PCB209 was acquired
through the Childhood Cancer Registry for Familial and
Sporadic Tumors (CCuRe-FAST) tumor banking program.
PCB209 tumor tissue was received 24 hours after surgical
resection. Tumor tissue was minced and digested with
collagenase (10mg/ml) overnight at 4°C. Dissociated cells
were cultured in RPMI-1640 media (11875085; 0ermo
Fisher Scientific, Waltham, MA, USA) supplemented with
10% fetal bovine serum (FBS) (26140079; 0ermo Fisher
Scientific) and 1% penicillin-streptomycin (15140-122;
0ermo Fisher Scientific) and then incubated at 37°C/5%
CO2. Tumor tissue was sent overnight to the Jackson
Laboratory (JAX), where the PDX model of PCB209 was
created. 0e PCB-209 PDX model was assigned to the JAX
model ID TM00381. All patients enrolled in CCuRe-FAST
provided informed consent, and clinical and pathologic
information are maintained in a deidentified database. All
aspects of the study were reviewed and approved by the
Oregon Health & Science University (OHSU) Institutional
Review Board (IRB).
4.2. PCB209 Whole Genome Sequencing Analysis. Isolated
DNA was sequenced with the Illumina HiSeq 1000 in
paired-end mode and quality filtered by Illumina BaseCall
software. Reads were mapped to the reference human
genome (NCBI build 36.1, hg18) using Bowtie [25], and
probable PCR duplicates were flagged and removed. A
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Figure 4: PCB-209 xenograft-derived in vivo trial results. Mean tumor volume of all treatment cohorts of the Jackson Lab-based PCB-209
patient-derived xenograft (PDX) model in vivo preclinical studies. (a) Tumor growth of crizotinib-treated PDX mice (n� 6) versus control
(n� 4). (b) Tumor growth of carfilzomib-treated PDX mice (n� 7) versus control (n� 4). (c) Tumor growth of panobinostat-treated PDX
mice (n� 8) versus control (n� 4). (d) Tumor growth of celecoxib- (n� 5), trametinib- (n� 5), and celecoxib + trametinib-treated (n� 4)
PDXmice versus control (n� 4). (e) Tumor growth of ABT-737 (n� 7), midostaurin (n� 8), and ABT-737 +midostaurin-treated PDXmice
(n� 2) versus control (n� 4). 0e p value was calculated without the midostaurin +ABT-737 due to low sample population, noted by the
asterisk. 0e low number of models for the combination experiment is due to microbiological considerations at the Jackson Laboratory. In
(a–e), the endpoint was treatment days 30–32.
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SNV was identified as a possible variant when the variant
had at least three support reads and constituted at least
10% of position coverage. Somatic variants were called if
the variant had at least 8x coverage in the matched normal,
and the variant occurred in less than two reads and 2% of
the coverage.
Copy number variations were quantified as the segmented
normalized log2-transformed tumor/normal exon coverage
ratios. CNVer [26] was used to call genes as gained or lost,
requiring an exon copy number gain or loss of 30% (ratio ≥1.3
or ≤0.7) to call the gene as gained or lost. Sequencing analysis
is based on a previously published approach [27].
4.3. PCB209 and PCB209X RNA Deep Sequencing Analysis.
0e PCB209 transcriptome library was sequenced with the
Illumina HiSeq 1000 in paired-end mode and filtered by
Illumina BaseCall software. Reads were trimmed to 85-
mers and aligned to the reference human genome (NCBI
build 36.1, hg18) using Bowtie [25]. Coverage of reads
mapped to the transcript was summed at each position,
and the result was divided by the transcript length times
the number of reads in the sample multiplied by one
million.
4.4. Chemical Screens. PCB209 primary tumor culture was
screened using a custom 60 agent target inhibitor screen
denoted the Pediatric Preclinical Testing Initiative Screen
Version 2.1 (PPTI screen). All screening agents were
tested at either [10, 100, 1000, 10,000 nM] or [100, 1000,
10,000, 100,000 nM] based on published activity range of
each compound. Compounds were purchased from third-
party vendors including Selleck Chem and Sigma-
Aldrich. PCB209 primary cell cultures in RPMI growth
media were plated at 5000 cells/well in 384-well plates
preprinted with drug. Screening plates were incubated at
37°C/5% CO2, for 72 hours. Cell viability was assessed by
CellTiter-Glo® Luminescent Cell Viability Assay (cat.G7570, Promega, Madison, WI) following the manu-
facturer’s protocol, and luminescence was quantified with
BioTek Synergy HT plate reader (BioTek, Winooski, VT).
Single agent IC50 values were computed via hill curve-
fitting in Microsoft Excel followed by manual curation
and refitting.
4.5. Patient-Derived Xenograft Model Development. All as-
pects of tissue sharing were reviewed and approved by the
Oregon Health & Science University Institutional Review
Board. PDX models for PCB209 were generated at JAX by
implanting tumor tissue pieces into 4–6-week-old female
immunodeficient NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG)
mice. When the engrafted tumor grew to ∼1000mm3, the
tumor was harvested and split into multiple 3–5mm3 pieces
and reimplanted into a new cohort of five 6–8-week-old
female NSG mice for passage 1 expansion, and additional
fragments were sent for quality control assessment (see
below) or cryopreserved in 10%DMSO. P1 tumors that grew
to 1000mm3 were harvested and divided into four sections,
one each for quality control, snap freezing for genomics,
RNALater (Ambion) for RNA-seq, and sectioning into
3–5mm3 pieces and cryopreservation in 10% DMSO.
PDX model development quality control procedures
include testing the primary tumor for LCMV (lymphocytic
choriomeningitis virus), bacterial contamination, and tumor
cell content. 0e P0 and P1 tumor fragments were DNA
fingerprinted using a Short Tandem Repeat (STR) assay to
ensure model provenance in subsequent passages.
Immunohistochemistry (IHC) for human CD45
(IR75161-2, Agilent Technologies) was performed on
engrafted tumor tissue embedded in paraffin blocks to
identify lymphomagenesis. IHC for human ki67 (IR62661-2,
Agilent Technologies) and vimentin (IR63061-2, Agilent
Technologies) were used to ensure the propagated tumors
were human rather than murine. Engrafted tumor H&E
sections were reviewed by a board-certified pathologist
(RGE) to evaluate morphological feature concordance be-
tween the engrafted tumor and the patient tumor.
Model information is accessible at http://tumor.
informatics.jax.org/mtbwi/pdxDetails.do?
modelID�TM00381.
4.6. Probabilistic Target Inhibition Map (PTIM) Modeling.
We used PTIM modeling [16, 17, 28] to integrate PCB209
drug data with RNA sequencing data to select a personalized
drug combination for PCB209.
RNA-seq integration. We use quantified expression data
to eliminate possible false positives from chemical screen
results and promote true positives among PTIM modeling
targets. Here, we threshold minimummean gene expression
across the primary and PDX RNA-seq at 4 FPKM to de-
termine potential inclusion in the PTIM computational
model. RNA-seq data are integrated as below:
(i) T: drug screen targets
(ii) G: drug screen targets with RNA-seq expression
(iii) Primary(x): gene expression of target x in primary
tumor sample
(iv) PDX(x): gene expression of target x in explanted
PDX tumor sample
(v) µ(x): [primary(x) + PDX(x)]/2
(vi) ∀x∈T∩G if µ(x)≥ 4, keep target x for consideration
(vii) ∀x∈T∩G if µ(x)< 4, remove target x from
consideration
(viii) ∀x∉T∩G keep target x for consideration
PTIM modeling identified the two-drug combination of
ABT-737 +midostaurin as a promising combination for
PCB-209. 0e PTIM modeling dataset is provided in Sup-
plemental Table 6.
4.7.MorphoproteomicAnalysis. Morphoproteomic analysis
was performed by Dr. Robert Brown independent of
the chemical screening, sequencing, and PTIM
modeling approaches to personalized therapy assignment.
Morphoproetomic analysis has been previously described
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in multiple publications [29–31]. Neither PTIM modeling
nor chemical screening of genomic/transcriptomic data
were involved in the selection of the IHC-motivated drug
combination.
4.8. Statistics. In the PCB209 PDX experiment, the signif-
icance of variation in tumor volume with treatment was
assessed with Kruskal–Wallis analysis of variance (KW
ANOVA) statistical tests. All statistical testing was two-sided
with a significance level of 5%.
4.9. Study Approval. All patients enrolled in CCuRe-FAST
provided informed consent. All aspects of the study were
reviewed and approved by the Oregon Health & Science
University (OHSU) Institutional Review Board (IRB).
All animal procedures performed at the Jackson Labo-
ratory were conducted in accordance with the Guidelines for
the Care and Use of Laboratory Animals and were approved
by the Institutional Animal Care and Use Committee at the
Jackson Laboratory.
Data Availability
High-throughput RNA sequencing data are available
through the Gene Expression Omnibus (GEO, Accession ID
GSE138269), and the whole genome sequencing data are
available through the European Genome-Phenome Archive
(EGA, Accession ID EGAS00001003981). Accessing pro-
tected data will require adhering to the requirements of the
respective database systems.
Ethical Approval
All aspects of the study were reviewed and approved by the
Oregon Health & Science University (OHSU) Institutional
Review Board (IRB). All animal procedures performed at the
Jackson Laboratory were conducted in accordance with the
Guidelines for the Care and Use of Laboratory Animals and
were approved by the Institutional Animal Care and Use
Committee at the Jackson Laboratory.
Consent
All patients enrolled in CCuRe-FAST provided informed
consent.
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Supplementary Materials
Supplementary Table 1. Commercial ex vivo assay results
and concordance—table of results transcribed from two
separate commercial ex vivo chemosensitivity assays per-
formed for the patient. Provides comparison and concor-
dance of results between commercial assays for agents tested
on both commercial screens. Supplementary Table 2. Ex vivo
assay results—results of ex vivo sensitivity assays from
commercial services and the research-level ex vivo targeted
therapy screen. Supplementary Table 3. PCB209 drug screen
results—sensitivity results from the research-level ex vivo
targeted therapy sensitivity assay. 0e same drug screen was
tested both on primary PCB209 cancer cells, as well as cancer
cells taken from the PCB209 patient-derived xenograft
(PCB209X). Supplementary Table 4. DNA and RNA se-
quencing data—results from DNA sequencing experiments
(identifying mutations and copy number variations) and
RNA sequencing experiments (quantifying gene expression)
aligned across individual genes. Supplementary Table 5.
Morphoproteomics—results from consultative proteomics
report performed for PCB209, detailing scores, and locations
of analyzed proteins from immunohistochemical experi-
ments. Supplementary Table 6. Merged drug screen and
sequencing—merged and aligned data from DNA and RNA
sequencing experiments and the PCB209 primary culture
and patient-derived xenograft culture research-level drug
screen results, organized at the drug and gene levels. Sup-
plementary Figure 1. Timeline of events described in this
manuscript regarding patient care, commercial and re-
search-level experiments, recurrence, and outcomes. (Sup-
plementary Materials)
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